Identifying the biological fingerprints of fatigue

Lead Research Organisation: Newcastle University
Department Name: Institute of Cellular Medicine

Abstract

Context of the research:
Chronic fatigue syndrome (CFS) affects 1 in 300 people in the UK and is associated with a significant healthcare-related cost to the society. Severe, persistent fatigue is a key symptom of CFS and a major factor leading to loss of productivity in this illness. The cause of CFS and the underlying biological mechanisms of fatigue are poorly understood. As a result, accurate diagnosis of CFS can be difficult and effective treatment is not available. A growing body of evidence suggests that CFS may be linked to a faulty immune system. However, in what ways the immune system is not working properly is not clear. Therefore, by uncovering the abnormalities of the immune system in CFS in detail, it will help make the diagnosis of CFS easier and more accurate as well as give us clues to develop effective treatment of this condition.

Since the diagnosis of CFS is unreliable at present, a group of "CFS" patients may in fact consist of individuals with different diseases. This presents a major obstacle to the progress of CFS research and may also explain why data from different CFS research studies are often conflicting. Therefore, in order to better understand the underlying biological mechanisms of CFS, a different approach is needed. Recent data show that intense fatigue is also a common symptom for many chronic conditions. Interestingly, most of these conditions are due to a faulty immune system. Furthermore, research also suggests that severe fatigue in these various conditions is driven by similar biological mechanisms. If so, we may be able to find out the underlying defects of the immune system causing disabling fatigue in CFS by using one of these chronic conditions as a disease model. This is precisely what we will do in this study.

We will carry out a comprehensive analysis of the immune system of a large number of patients with a condition called primary Sjögren syndrome (PSS). We will analyze the data obtained from these experiments to ind out what abnormalities of the immune system are linked to fatigue. Since these experiments typically produce a vast amount of data, we will apply statistical methods and mathematical modelling specifically designed to analyse large volumes of biological data (known as bioinformatics and biostatistics) in order to identify the biological "fingerprints" of fatigue. We will then test whether these biological fingerprints of fatigue are present in CFS patients and whether it will help us to diagnose CFS more accurately.

We chose PSS as a disease model for several reasons. (i) PSS and CFS have many shared clinical and biological features including profound fatigue. (ii) Clinical samples from over 550 PSS patients across the UK, as well as their clinical data, are available for this study. Access to such samples is a distinct advantage because this is one of the largest clinical sample collections in PSS in the world. It would be time-consuming, labour-intensive and expensive if we had needed to collect the same amount of clinical samples and accompanied clinical data from fresh. (iii) There are well-established diagnostic criteria for PSS and so this avoids the problem of studying patients with potentially mixed diagnoses as in the case of studying CFS patients.

Aims of the study, potential applications and benefits:
The main objective of this study is to find the biological fingerprints of fatigue. By doing so, it will improve our understanding of the biological mechanisms of fatigue. The data will enable us to develop treatments for the fatigue that plagues so many patients with CFS and other chronic conditions. It will also help us to design a clinical test for the diagnosis of CFS.

Technical Summary

This study aims to identify the biological fingerprints of fatigue using primary Sjogren's syndrome (PSS), an autoimmune condition with several clinical and biological features similar to chronic fatigue syndrome (CFS) including intense fatigue, as a disease model. We will then test whether these biological fingerprints are also present in patients with CFS.

We will perform whole blood gene expression profiling (using genome-wide microarray) and measure serum markers of immune dysregulation (using fluorescent bead-based multiplex technology) of an existing biobanked samples from a large cohort of clinically well-characterized PSS patients (the UK PSS registry). Further information concerning the cohort can be found on the cohort website www.sjogrensregistry.org and Annex 1. The data from these experiments will be analyzed using various bioinformatics techniques in order to identify a biological profile of fatigue, which will be validated using a second blinded test cohort of PSS patients. We will also investigate whether the biological profile changes over time and responds to biological treatment of fatigue in PSS patients. The data from these investigations will then be integrated to identify a set of biomarkers that will maximally discriminate fatigued subjects from non-fatigued individuals. Finally, we will test whether these biomarkers of fatigue are present in CFS patients and if so, whether they can be used to correctly classify CFS from active or sedentary healthy individuals.

Planned Impact

Chronic fatigue is a global health problem. Severe, debilitating fatigue is not only the cardinal symptom of chronic fatigue syndrome (CFS), but also a common problem in many chronic diseases, cancers and a side-effect of many treatments such as cytokine-based therapies and chemotherapies. In the wider health-economic context, chronic fatigue is a common complaint in primary care settings and is a major cause of productivity loss at work places and associated poor quality of life. It places a considerable burden on the NHS. It has been estimated to cost over £633 millions every year in a survey carried out in 2000. In the US, a study in 2009 estimated an annual loss of over US$136 billion in productivity.

Despite being a common symptom, fatigue is a poorly understood phenomenon and the treatment of fatigue is largely ineffective. In addition, adequate assessment of a complex, multi-faceted symptom such as fatigue remains a challenge to researchers and clinicians alike.

Therefore, by seeking the biological fingerprints of fatigue using a hypothesis-free approach, the data generated from this study will have a substantial scientific and societal impact. In the short term, it will address a key knowledge gap in the biological mechanisms of fatigue and CFS as well as inform future directions of research in these areas. The development of a recognized biomarker would ease the stigma sometimes associates with CFS/ME through the lack of such a diagnostic.

In the longer term, the biomarkers of fatigue identified in this proposal can be used to study chronic fatigue in other conditions. These biomarkers may also facilitate the development of targeted therapies, provide an objective assessment of responses to treatments in clinical trials and improve our diagnosis and stratification of fatigue and CFS. The development of any drugs or therapies would be of potential benefit to pharmaceutical companies and the economy.

Publications

10 25 50
 
Description Committee member of the BSR Management Guideline development group for primary Sjogren's syndrome
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Galvani Bioelectronics Rheumatology Advisor Board Meeting London 2018
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Invited to join the Outcome Measures Online Training Advisory Committee
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Invited to join the Sjogren's Syndrome Foundation Clinical Trial Consortium (US)
Geographic Reach North America 
Policy Influence Type Participation in a advisory committee
 
Description NIHR Bioresource Meeting - prelude to IMID-Bio
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Arthritis Research UK Education Grant
Amount £45,332 (GBP)
Organisation Versus Arthritis 
Start 08/2014 
End 07/2015
 
Description Arthritis Research UK project grant
Amount £160,000 (GBP)
Funding ID 21183 
Organisation Versus Arthritis 
Start 05/2016 
End 11/2017
 
Description Arthritis Research UK project grant
Amount £159,609 (GBP)
Funding ID 21183 
Organisation Versus Arthritis 
Start 05/2016 
End 10/2017
 
Description Capital Investment in Human Tissue Banking and Linked Data, in Partnership with Charities
Amount £1,700,000 (GBP)
Funding ID MR/R014191/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2017 
End 03/2021
 
Description Centre Grant
Amount £150,000 (GBP)
Funding ID 20018 
Organisation Versus Arthritis 
Start 07/2015 
End 06/2017
 
Description Commercial funding
Amount £65,000 (GBP)
Organisation ElectroCore LLC 
Sector Private
Country United States
Start 09/2018 
End 08/2019
 
Description Develop objective assessment tools for measuring fatigue in clinical studies.
Amount £200,750 (GBP)
Organisation National Institute for Health Research 
Department NIHR Newcastle Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 05/2018 
End 10/2020
 
Description Doctoral Training Fellowship
Amount £177,122 (GBP)
Funding ID 20169 
Organisation Versus Arthritis 
Start 04/2013 
End 03/2017
 
Description EU IMI
Amount € 8,000,000 (EUR)
Organisation European Commission 
Department Innovative Medicines Initiative (IMI)
Sector Multiple
Country European Union (EU)
Start 01/2019 
End 12/2024
 
Description Horizon2020
Amount € 10,000,000 (EUR)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2017 
End 06/2020
 
Description Identifying objective assessment of fatigue
Amount £250,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Newcastle Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 04/2018 
End 03/2021
 
Description Project grant
Amount £52,884 (GBP)
Organisation The JGW Patterson Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2016 
End 09/2017
 
Description Proximity to Discovery
Amount £250,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2015 
End 12/2016
 
Description Stratified Medicine
Amount € 600,000 (EUR)
Organisation Foreum 
Sector Charity/Non Profit
Country Switzerland
Start 08/2018 
End 07/2021
 
Title A large genowide expression datasets 
Description Using the biological samples from the UKPSSR, we have now generated data on whole genome expression analyses of whole blood samples from over 300 PSS patients and around 50+ healthy controls. 
Type Of Material Biological samples 
Year Produced 2016 
Provided To Others? Yes  
Impact The data were generated in two phases. The data from phase 1 have been published and deposited in the GEO database which is accessible to the public (accession number GSE66795) The phase 2 data are currently being used for our own study and in another study in collaboration with a research group in France. We are expecting to publish the data in the near future. 
 
Title Newcastle Sjogren's syndrome stratification tool 
Description This tool enables clinicians and researchers to sub classify patients with primary Sjogren's syndrome with 4 distinct subtypes - each with different clinical features and distinct biological profiles and response to different therapies. 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2018 
Provided To Others? No  
Impact The manuscript is currently under peer-review, once accepted for publication, it will be made available for researchers 
 
Title UKPSSR biological materials 
Description Serum, DNA, RNA, PBMC 
Type Of Material Biological samples 
Year Produced 2010 
Provided To Others? Yes  
Impact Serum samples were sent to Liverpool University for the study of a novel autoantibody in primary Sjogren's syndrome - study ongoing DNA samples were sent to Oklahoma Medical Research Foundation for a genome-wide association study in primary Sjogren's syndrome. Various other biological samples have subsequently been sent to several other collaborative partners including industrial partners. It has led to 15 peer-reviewed publication, additional grant funding, some of the studies are ongoing 
 
Title UK primary Sjogren's syndrome registry 
Description Collection of >750 clinically well-characterised patients with associated biobanked samples 
Type Of Material Database/Collection of data 
Year Produced 2010 
Provided To Others? Yes  
Impact By 2014, it has led to 15 peer-reviewed publications, leveraged additional research funding and many new research collaborations. 
URL http://www.sjogrensregistry.org
 
Description Development of a user-informed invention to improve the function of primary Sjogren's syndrome patients 
Organisation Northumbria University
Country United Kingdom 
Sector Academic/University 
PI Contribution provide intellectual input on study design, using UKPSSR data for inviting partient to participating in this study
Collaborator Contribution Assistance in data analysis and non-pharmacologica aspect of intervention development
Impact Partnership has only just started
Start Year 2013
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases 
Organisation King's College London
Department School of Biomedical Sciences KCL
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases 
Organisation Queen Mary University of London
Department School of Biological and Chemical Science QMUL
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases 
Organisation University of Cambridge
Department Cambridge-Africa
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases 
Organisation University of Glasgow
Department Mental Health Rights Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases 
Organisation University of Manchester
Department Mancester Breast Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description Identifying the biological signature of fatigue 
Organisation Great Western Hospitals NHS Foundation Trust
Department Rheumatology Department Great Western Hospitals
Country United Kingdom 
Sector Public 
PI Contribution PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project
Collaborator Contribution Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment
Impact Project been awarded recently, to be started in early 2012
Start Year 2011
 
Description Identifying the biological signature of fatigue 
Organisation Newcastle University
Department Institute for Ageing and Health
Country United Kingdom 
Sector Academic/University 
PI Contribution PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project
Collaborator Contribution Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment
Impact Project been awarded recently, to be started in early 2012
Start Year 2011
 
Description Identifying the biological signature of fatigue 
Organisation Newcastle University
Department Institute for Cell and Molecular Biosciences
Country United Kingdom 
Sector Academic/University 
PI Contribution PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project
Collaborator Contribution Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment
Impact Project been awarded recently, to be started in early 2012
Start Year 2011
 
Description Identifying the biological signature of fatigue 
Organisation Newcastle University
Department School of Computing Science
Country United Kingdom 
Sector Academic/University 
PI Contribution PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project
Collaborator Contribution Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment
Impact Project been awarded recently, to be started in early 2012
Start Year 2011
 
Description Identifying the biological signature of fatigue 
Organisation University Hospitals Birmingham NHS Foundation Trust
Department Rheumatology University Hospitals Birmingham
Country United Kingdom 
Sector Public 
PI Contribution PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project
Collaborator Contribution Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment
Impact Project been awarded recently, to be started in early 2012
Start Year 2011
 
Description Reseach Collaboration_ Resolve 
Organisation Resolve Therapeutics, LLC
PI Contribution Clinical and Scientific expertise, clinical trial design, serving as Chief Investigator and recruitment of patients to a phase 2 clinical trial in Sjogren's syndrome sponsored by the company
Collaborator Contribution Sponsor of the clinical trials and funding of the exploratory research projects using the clinical samples collected from clinical trial participants
Impact Clinical trial ongoing
Start Year 2017
 
Description Research Collaboration 
Organisation ElectroCore LLC
Country United States 
Sector Private 
PI Contribution We carried out a pilot study which has helped us to determine the immunological tests to be included in the main study
Collaborator Contribution The company provide research fund to enable us to conduct the pilot study while we are waiting for full regulatory approval to start the main study
Impact The pilot study was presented at the American College of Rheumatology Annual Meeting in November 2017, and won the best abstract award in Sjogren's syndrome. In Dec 2017, the company agreed to provide additional funding to extend the pilot study to include other patient group, we are currently awaiting for regulatory approval to commence the study.
Start Year 2016
 
Description Research Collaboration - Interferon signature in PSS 
Organisation Erasmus University Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution Providing samples for research and contribute to research design, data analysis and interpretation
Collaborator Contribution Conducting experiments
Impact Publications
Start Year 2014
 
Description Research Collaboration_ MedImmune 
Organisation MedImmune
Country United States 
Sector Private 
PI Contribution Provide clinical and scientific expertise as well as clinical and associated research data derived from corresponding biobanked samples
Collaborator Contribution Data analysis
Impact Project only just started, no outcome to report yet
Start Year 2018
 
Description Research Collaboration_Novartis 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution Provision of clinical/scientific expertise and anonymised clinical data
Collaborator Contribution Data analysis
Impact Only began recently.
Start Year 2017
 
Description Research Grant application 
Organisation University of Stavanger
Department Immunology
Country Norway 
Sector Academic/University 
PI Contribution Provide biobanked DNA and serum samples for the research project, if the application to the Norwegian Research Council is successful
Collaborator Contribution Conduct the experiments described in the grant application
Impact Awaiting outcome of the application
Start Year 2012
 
Description Research collaboration 
Organisation The Binding Site
Country Global 
Sector Private 
PI Contribution Provide biobanked serum sample and anonymised clinical data for the research project
Collaborator Contribution Analyse the samples for the agreed analytes of interest and provide support in data analysis. All raw data generated will be returned to the UKPSSR for storage and future use
Impact Analysis complete, preparing manuscript for publication
Start Year 2012
 
Description Research collaboration - exploratory study 
Organisation ElectroCore LLC
Country United States 
Sector Private 
PI Contribution Carry our the research activity
Collaborator Contribution provide the device for the research free of charge
Impact Research project has not commenced yet as awaiting full regulatory approval
Start Year 2016
 
Description Research collaboration - validation of Stratified Medicine 
Organisation University Paris Sud
Country France 
Sector Academic/University 
PI Contribution Generate original data
Collaborator Contribution Provide anonymised data for validation
Impact Oral presentation at American College of Rheumatology Annual Conference and Won the best abstract prize in Sjogren's syndrome
Start Year 2016
 
Description Research collaboration - validation of Stratified Medicine 
Organisation University of Stavanger
Country Norway 
Sector Academic/University 
PI Contribution Generate original data
Collaborator Contribution Provide anonymised data for validation
Impact Oral presentation at American College of Rheumatology Annual Conference and Won the best abstract prize in Sjogren's syndrome
Start Year 2016
 
Description Research collaboration - validation of Stratified Medicine 
Organisation University of Strasbourg
Country France 
Sector Academic/University 
PI Contribution Generate original data
Collaborator Contribution Provide anonymised data for validation
Impact Oral presentation at American College of Rheumatology Annual Conference and Won the best abstract prize in Sjogren's syndrome
Start Year 2016
 
Description Research collaboration_GSK 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Provision of clinical and scientific expertise, anonymoised clinical data and biobanked samples
Collaborator Contribution Analysis of data and biobanked samples
Impact Project ongoing
Start Year 2017
 
Title Newcastle Sjogren's syndrome Stratification Tool 
Description This enable researchers and clinicians to stratify patients with primary Sjogren's syndrome into 4 phenotypes with distinct clinical and biological profiles. 
Type Support Tool - For Fundamental Research
Current Stage Of Development Initial development
Year Development Stage Completed 2018
Development Status Under active development/distribution
Impact This stratification tool can potentially impact on future clinical trial design, therapeutic development and management of patients with primary Sjogren's syndrome 
 
Description A talk_British Sjogren's Syndrome Association Annual meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Give a presentation on fatigue in Sjogren's syndrome - its possible pathobiological basis and management
Year(s) Of Engagement Activity 2017
 
Description A talk_Fighting Fatigue (GSK) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Third sector organisations
Results and Impact To give a presentation on the pathobiology of fatigue for employees within GSK
Year(s) Of Engagement Activity 2017
 
Description A talk_Sjogren's syndrome Symposium (Novartis, Basel campus) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Third sector organisations
Results and Impact Give a presentation on the impact and possible pathobiological basis of fatigue in Sjogren's syndrome, and as a panel member for the symposium
Year(s) Of Engagement Activity 2018
 
Description EULAR annual meeting (Rome, 2015) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact I give a plenary talk on the current research in primary Sjogren's syndrome at the conference
Year(s) Of Engagement Activity 2015
 
Description Invited Talk_ Lausanne, Switzerland 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Keynote talk to Rheumatologists on clinical and research advances in Sjogren's syndrome
Year(s) Of Engagement Activity 2017
 
Description Invited talk 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Invited speaker at the European League Against Rheumatism Annual Conference, Amsterdam
Year(s) Of Engagement Activity 2018
 
Description Lecture 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Teaching on Sjogren's syndrome in a 3-day Rheumatology update course held in Flavia, Sicily, Italy. Most of the delegates are practicing rheumatologists and general physicians from Italy.
Year(s) Of Engagement Activity 2018
 
Description NIHR BRC Impact Showcase, Newcastle, 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Showcase event attended by senior figures from the Department of Health and major charities including Versus Arthritis. The CEOs of the Trust and University attended. Musculoskeletal presentations included patient presentations and videos. Ken Baker was awarded a prize for best oral presentation. Sir John Burn and Dame Jackie Daniel presented their vision for Newcastle.
Year(s) Of Engagement Activity 2018
URL https://www.newcastlebrc.nihr.ac.uk/events/nihr-newcastle-biomedical-research-centre-impact-showcase...
 
Description Proximity to Discovery themed week 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact This is a week of engagement activity targeting senior members of pharmaceutical/biotechnology industry to promote collaboration.
representatives from 5 pharmaceutical companies and a biotech company attended the meeting.
All companies showed great interest in our research into Sjogren's and fatigue.
Year(s) Of Engagement Activity 2016
 
Description Scientific Advisory Board 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact I have served on scientific advisory board for several pharmaceutical companies planning early phase clinical trials in Sjogren's syndrome and in fatigue.
Year(s) Of Engagement Activity 2014,2015,2016,2017
 
Description Talk (BSR annual conference, 2014) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Geographic Reach National
Primary Audience Health professionals
Results and Impact Improve the profile of fatigue research

New collaborative research being established
Year(s) Of Engagement Activity 2014
 
Description Talk (CFS/ME collaborative, Bristol, 2014) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Raising interest in the area of my research

Dissemination of research idea and data
Year(s) Of Engagement Activity 2014
 
Description Translational research partnership with several pharmaceutical companies to develop/test novel therapeutic targets for primary Sjogren's syndrome 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? Yes
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Consultation agreements, collaborative research activities

Facilitate development of novel therapies for primary Sjogren's syndrome
Year(s) Of Engagement Activity 2012,2013,2014
 
Description collaboration with Cambridge Patient Led Research Hub to develop a secured patient online portal for symptom tracking 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact This is the start of a Patient led project to develop a secured online portal for patients with primary Sjogren's syndrome to track their own symptoms, but also have the capacity to support research and to linked to other research databases such as the UK primary Sjogren's syndrome registry
Year(s) Of Engagement Activity 2019